iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Cohance Lifesciences and Suven Pharma Join Forces in Landmark Merger; Stock Surge 12%

1 Mar 2024 , 11:26 AM

A proposed plan of amalgamation for the combination of Suven Pharmaceuticals Limited and Cohance Lifesciences Limited was announced on February 29.

According to a press release from Suven Pharmaceuticals, the entire deal is anticipated to be completed within the next 12 to 15 months, pending the receipt of all necessary shareholder and regulatory approvals. 

Leading global private equity fund Advent International selected Kotak Mahindra Capital and Citi as advisors for deal aspects like swap ratio, due diligence, and fairness opinion. The merger process for its portfolio companies Suven Pharmaceuticals and Cohance Lifesciences was started on February 7, 2024, and Moneycontrol was the first to report it.

Beyond its present revenue base, the combination will position Suven as a diversified API (Active Pharmaceutical Ingredient) and CDMO (Contract Development and Manufacturing Organization) leader in India, the business also disclosed to exchanges. 

It is anticipated that the combined company will rank among India's top integrated CDMO providers. Scale and synergy benefits would be tremendous with a substantially broader client base and an enhanced capacity of 2,650 kL.

All Cohance shareholders will get shares of Suven upon the scheme's implementation, based on the swap ratio, at a ratio of 11 shares of Suven for every 295 Cohance shares. The NSE and BSE will be the trading platforms for the newly issued shares of Suven. Advent entities will possess 66.7 percent of the combined business, while public shareholders will hold 33.3% (prior to ESOP dilution).

Suven Pharma's stock surged by 12% during morning trading on March 1, following the company's announcement of a merger scheme with Cohance Lifesciences. By 11.24 am, Suven Pharma shares were up approximately 7.75%, trading at ₹677.75 on the National Stock Exchange.

For feedback and suggestions, write to us at editorial@iifl.com

Suven Pharma reports 56.6% decline in net profit, revenue falls 37.9%

Related Tags

  • Cohance Lifesciences
  • merger
  • Suven Pharma
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

closeIcon

Get better recommendations & make better investments

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp